|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||61.56 - 62.42|
|52 Week Range||46.01 - 66.10|
|PE Ratio (TTM)||24.43|
|Forward Dividend & Yield||1.60 (2.67%)|
|1y Target Est||N/A|
Smoking, which causes many lung cancer cases, has made advanced lung cancer a big market for pharmaceutical companies, and the competition has been fierce.
Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...
Moody's Investors Service, ("Moody's") has affirmed the ratings on four classes in Bear Stearns Commercial Mortgage Securities Trust 2007-PWR15, Commercial Mortgage Pass-Through Certificates, ...
While Merck & Co., Inc. (NYSE:MRK) had gotten off to a modest pace to start the year, the last few trading sessions have been rather explosive. Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. All told, Merck stock is up more than 10% this year.
Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.
How Is Amgen Positioned for 2018? In January 2018, the FDA approved Amgen’s (AMGN) supplemental Biologics License Application (or sBLA) for Xgeva. Xgeva is used for the prevention of skeletal-related events in individuals with bone metastasis from solid tumors.
Bristol-Myers Squibb Company (NYSE:BMY) delivered an ROE of 27.38% over the past 12 months, which is an impressive feat relative to its industry average of 11.69% during the same period.Read More...
Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent. A cocktail of immunotherapy Keytruda and two chemotherapy medicines helped lung cancer patients live longer and stopped the disease from advancing, early results from a study showed, Merck said.